IGF2
Insulin-like growth factor 2
Also known as: C11orf43, FLJ44734, IGF-II, IGF2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01344
- Gene
- IGF2
- Ensembl
- ENSG00000167244
- Chromosome
- 11
- Canonical length
- 180 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins
- Subcellular location
- Golgi apparatus
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region overlaps this gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2010]
Canonical amino-acid sequenceUniProt
180 residues, UniProt reviewed canonical sequence.
>P01344|IGF2
1 MGIPMGKSML VLLTFLAFAS CCIAAYRPSE TLCGGELVDT LQFVCGDRGF YFSRPASRVS
61 RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV LPDNFPRYPV GKFFQYDTWK
121 QSTQRLRRGL PALLRARRGH VLAKELEAFR EAKRHRPLIA LPTQDPAHGG APPEMASNRKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IGF2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 2,598 nTPM
Expression across tissuesHPA
Tissue
- placenta: 2,598 nTPM
- liver: 369 nTPM
- fallopian tube: 121 nTPM
- tongue: 107 nTPM
- choroid plexus: 99 nTPM
- adipose tissue: 93 nTPM
Single-cell type
- extravillous trophoblasts: 411 nCPM
- thymic myoid cells: 305 nCPM
- migrating cytotrophoblasts: 150 nCPM
- syncytiotrophoblasts: 149 nCPM
- leydig cells: 138 nCPM
- cytotrophoblasts: 93 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 618 nTPM
- cerebral cortex: 222 nTPM
- basal ganglia: 106 nTPM
- medulla oblongata: 74 nTPM
- thalamus: 51 nTPM
- pons: 50 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IGF2.
Disease | AllUniProt
Conditions IGF2 is implicated in, by any mechanism.
- Silver-Russell syndrome 1 (SRS1) MIM:180860
- Silver-Russell syndrome 3 (SRS3) MIM:616489
Disease | GeneticClinVar
24 pathogenic / likely-pathogenic of 182 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Silver-Russell syndrome 3
- Silver-Russell syndrome 1
- Beckwith-Wiedemann syndrome
- Wilms tumor 1
- Colorectal cancer
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.13
- gnomAD pLI
- 0.04
- gnomAD missense Z
- 0.93
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- animal organ morphogenesis
- embryonic placenta development
- embryonic placenta morphogenesis
- exocrine pancreas development
- genomic imprinting
- glucose metabolic process
- in utero embryonic development
- insulin receptor signaling pathway
- insulin-like growth factor receptor signaling pathway
- negative regulation of muscle cell differentiation
- negative regulation of transcription by RNA polymerase II
- osteoblast differentiation
- positive regulation of activated T cell proliferation
- positive regulation of cell division
- positive regulation of cell population proliferation
- positive regulation of glycogen biosynthetic process
- positive regulation of insulin receptor signaling pathway
- positive regulation of MAPK cascade
- positive regulation of mitotic nuclear division
- positive regulation of multicellular organism growth
- positive regulation of organ growth
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of skeletal muscle tissue growth
- positive regulation of transcription by RNA polymerase II
- positive regulation of vascular endothelial cell proliferation
- regulation of DNA-templated transcription
- regulation of muscle cell differentiation
- striated muscle cell differentiation
Molecular functions
- growth factor activity
- hormone activity
- insulin receptor binding
- insulin-like growth factor receptor binding
- integrin binding
- protein serine/threonine kinase activator activity
- receptor ligand activity
- transmembrane receptor protein tyrosine kinase activator activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Insulin-like
- Insulin-like growth factor IGF-1/2
- Insulin/IGF/relaxin
- Insulin, conserved site
- Insulin-like superfamily
- Insulin/IGF/Relaxin family
- Insulin-like growth factor II E-peptide, C-terminal
- Insulin-like growth factor II
- Insulin-like growth factor II E-peptide
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IGF2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IGF2 as an antibody target. Whether an autoantibody or antibody against IGF2 could matter depends on whether native IGF2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IGF2 is annotated as secreted, so native IGF2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IGF2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...